Citigroup analyst Jason Bazinet maintains Spotify Technology (NYSE:SPOT) with a Buy and lowers the price target from $165 to $150.
SVB Leerink Maintains Outperform on Intellia Therapeutics, Raises Price Target to $158
SVB Leerink analyst Mani Foroohar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price target from $152 to $158.